User:Sukanya Raghavan (GU)/sandbox

Ann-Mari Svennerholm, MD, PhD
Ann-Mari Svennerholm is a Swedish professor of Infection and Immunity at the University of Gothenburg, Sweden. Ann-Mari has devoted her scientific career in studying the pathogenic and immune mechanisms of enteric bacteria such as enterotoxigenic Escherichia coli (ETEC), Helicobacter pylori (H. pylori) and Vibrio cholerae (V. cholerae). She has, together with Professor Jan Holmgren developed the oral cholera vaccine Dukoral and she is currently developing an oral vaccine against ETEC. This ETEC vaccine is currently in phase II clinical trials.

Education
Ann-Mari received her medical training at the Sahlgrenska University Hospital, Gothenburg, Sweden. She then went on to complete her PhD in Microbiology and Immunology at the University of Gothenburg. In her thesis, she described the development of a protective oral cholera vaccine based on inactivated bacterial whole cells and cholera toxin B subunit. This proposed vaccine was effectively able to induce protective IgA intestinal antibodies, and later became what is known as Dukoral. She has held numerous positions a the University of Gothenburg, including Professor of Infection and Immunity since 1994 and vice-dean of the faculty of medicine (Sahlgrenska Academy) 1999-2003.

Research
Ann-Mari's research group has focused on studying several aspects of disease and immunity in enterotoxin-induced diarrhoeal diseases including (1) development of diagnostic methods for detection and epidemiologic studies of enteropathogens (2) studies of pathogenic and immune mechanisms in H. pylori infections and gastric cancer (3) development of oral cholera and ETEC vaccines including phase I-III clinical trials (4) development of methods and basic studies of mucosal immune response to vaccines and infections in human. Between 2007-2011 her laboratory has been selected as the "WHO reference laboratory for research on ETEC".

Career
Ann-Mari has served on numerous national and international boards in the fields of infection, vaccine and global health. This includes the Swedish Research Council, Swedish Foundation for Strategic Research, and the Swedish Institute for Infectious Disease control in Sweden. Ann-Mari has been the chair for the WHO diarrhoeal and enteric vaccines advisory committee (DEVAC) and Norwegian research program for global health and vaccines (GLOBVAC). She has also been a member of the board of the international vaccine institute (IVI) in South Korea and at the International Center for diarrhoeal disease, Bangladesh (icddr,B). She has published more than 450 scientific publications in microbiology, epidemiology, mucosal immunology, infectious disease, vaccinology and biotechnology. Currently, her publications have been cited 23.128 times.

She has collaborated with research groups in the USA: Johns Hopkins &University of  Maryland, Baltimore, PATH enteric vaccines initiative program; in Europe: Sanger Institute, Cambridge,  Pasteur Institute, Paris; Institute of International Health, Bergen, Norway; several vaccine  research institutes in Holland, Italy  and Belgium;  in Asia: icddr,b, Dhaka, Bangladesh;  International vaccine institute, Seoul, Korea; National Institute of Hygiene, Hanoi, Vietnam and in Latin America: UMSA, La Paz, Bolivia; Laboratorio Diagnóstico Molecular, Guatemala City, Guatemala;  Mexico university, Mexico City; Instituto Nacional de Microbiologia, Buenos Aires; Universidad Peruana, Lima, Peru, Chile and in Africa:  Namru III, Cairo, Egypt;  different laboratories in  Kenya, Benin, Gambia and Zambia.

Awards and honours
In 2008, Ann-Mari was elected fellow of the Royal swedish academy of sciences (KVA).

- Eric Fernström Prize for young researchers for vaccine studies 1991.

- The Swedish Medical Society Prize (Torsten and Ragnar Söderberg’s Prize) together with Prof. Jan Holmgren for development of vaccines against cholera and enterotoxigenic E. coli, 1994.

- His majesty the Swedish King’s medal  (for scientific contributions  in biomedical research) 2018.